Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP), the biotechnology company behind the drug delivery system DehydraTECH, announced Thursday that its subsidiary Poviva Corp had been awarded four patents.
The patents, two in the US and two in Australia, bring Lexaria’s total to 15 granted patents, along with 60 pending applications around the world.
Collectively, the patents focus on the effective delivery to the body of cannabinoids, anti-inflammatory drugs, nicotine and vitamins.
The new patents specifically relate to methods of creating orally-ingestible, fat-soluble agents that can be infused into food or beverages. The idea is to create a result that can dissolve in fat, rather than water
Separately, Lexaria announced it was issuing 550,000 incentive stock options to employees and consultants of the company, as well as one director. The options are exercisable at a price of US$0.81 per share.
Lexaria stock closed at US$0.80 on Thursday.
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel